Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1671-1675

  Amid, Ali ^a   Barrowman, Nick ^a   Vijenthira, Abi ^a   Lesser, Pat ^a   Mandel, Karen ^a   Ramphal, Raveena ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Cancer; Chemotherapy; Children; Ferritin; Iron overload; Transfusion

Indexed keywords

FERRITIN;

ADOLESCENT; ARTICLE; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHILD; CHILDHOOD CANCER; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; HYPERFERRITINEMIA; INFANT; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD;

CANCER; CHEMOTHERAPY; CHILDREN; FERRITIN; IRON OVERLOAD; TRANSFUSION;

ADOLESCENT; BODY SURFACE AREA; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HUMANS; IRON METABOLISM DISORDERS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84881487433     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24629     Document Type: Article

References (29)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341:1986-1995.
2. Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci 2009; 66:3241-3261.
3. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115:239-252.
4. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78:487-494.
5. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2:27-30.
6. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586-4588.
7. Parkkila S, Niemelä O, Savolainen ER, et al. HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion 2001; 41:828.
8. Lichtman SM, Attivissimo L, Goldman IS, et al. Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol 1999; 61:262-264.
9. McKay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17:63-66.
10. Harrison P, Neilson JR, Marwah SS, et al. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol 1996; 49:853-856.
11. Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia: Manifestations and therapy. Am J Med Sci 2000; 319:73-78.
12. Jastaniah W, Harmatz P, Pakbaz Z, et al. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer 2008; 50:319-324.
13. Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56:368-371.
14. Halonen P, Mattila J, Suominen P, et al. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. Pediatrics 2003; 111:91-96.
15. Ruccione KS, Mudambi K, Sposto R, et al. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatr Blood Cancer 2012; 59:697-702.
16. Gurram MK, Newman W, Kobrinsly N. Prevalence of iron overload in pediatric oncology patients after blood transfusion. Clin Adv Hematol Oncol 2012; 10:363-365.
17. Worwood M. Serum ferritin. Clin Sci (Lond) 1986; 70:215-220.
18. Brittenham GM, Sheth S, Allen CJ, et al. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38:37-56.
19. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417-423.
20. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-578.
21. Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence, survival among children, adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; SEER Program. NIH; Pub. No. 99-4649, 1999.
22. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
23. Reddy K, Eng J, Carlson CA, et al. Iron overload in childhood cancer survivors. In International Conference of Long Term Complications of Treatment of Children and Adolescents for Cancer. Abstract. June 2012. Williamsburg, VA, USA.
24. Hallberg L, Hultén L, Gramatkovski E. Iron absorption from the whole diet in men: How effective is the regulation of iron absorption? Am J Clin Nutr 1997; 66:347-356.
25. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26:323-342.
26. Andrews NC, Ullrich CK, Fleming MD. Disorders of Iron metabolism and sideroblastic anemia. In: Orkin SH, Nathan DG, et al., editors. Nathan and Oski's hematology of infancy and childhood, 7th edition. Philadelphia: WB Sanders; 2009. pp 521-570.
27. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327-331.
28. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42:799-805.
29. Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114:1270-1275.